Generic Brilinta Availability

Brilinta is a brand name of ticagrelor, approved by the FDA in the following formulation(s):

BRILINTA (ticagrelor - tablet;oral)

Has a generic version of Brilinta been approved?

No. There is currently no therapeutically equivalent version of Brilinta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brilinta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
    Patent 6,251,910
    Issued: June 26, 2001
    Inventor(s): Guile; Simon & Ingall; Anthony & Springthorpe; Brian & Willis; Paul
    Assignee(s): AstraZeneca UK Limited
    Compounds of formula having the following stereochemistry ##STR1## wherein R, R.sup.1, R.sub.2, R.sup.3 and R.sup.4 are as defined in the specification. The compounds are useful as P.sub.2T receptor antagonists.
    Patent expiration dates:
    • July 15, 2018
      ✓ 
      Drug substance
  • Triazolo(4,5-d)pyrimidine compounds
    Patent 6,525,060
    Issued: February 25, 2003
    Inventor(s): David; Hardern & Anthony; Ingall & Brian; Springthorpe & Paul; Willis & Simon; Guile
    Assignee(s): Astrazeneca UK Limited
    Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and R1 through R3 are as defined in the specification.
    Patent expiration dates:
    • December 2, 2019
      ✓ 
      Patent use: REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Patent 7,250,419
    Issued: July 31, 2007
    Inventor(s): Hardern; David & Ingall; Anthony & Springthorpe; Brian & Willis; Paul & Guile; Simon
    Assignee(s): AstraZeneca AB
    The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Patent expiration dates:
    • December 2, 2019
      ✓ 
      Patent use: REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
    Patent 7,265,124
    Issued: September 4, 2007
    Inventor(s): Bohlin; Martin & Cosgrove; Steve & Lassen; Bo
    Assignee(s): AstraZeneca AB
    The invention provides new forms of a chemical compound of formula (I). The invention relates to forms of a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.
    Patent expiration dates:
    • July 9, 2021
      ✓ 
      Patent use: REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical compositions
    Patent 8,425,934
    Issued: April 23, 2013
    Assignee(s): AstraZeneca AB
    The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
    Patent expiration dates:
    • December 18, 2029
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 20, 2016 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)